Routine histopathological examination after female‐to‐male gender‐confirming mastectomy.
Published: 5th April 2018
Authors: S. M. J. Van Renterghem, J. Van Dorpe, S. J. Monstrey, J. Defreyne, K. E. Y. Claes, M. Praet et al.
The number of transmen seeking gender‐confirming surgery has risen steadily throughout the last decade. Pathologists are increasingly confronted with transmale mastectomy specimens. It is not clear whether routine histopathological examination is useful. This study explored the possible benefit of routine investigation through detailed description of lesions encountered in mastectomy specimens after female‐to‐male gender‐confirming surgery.
Breast tissue from a cohort of transmen was reviewed. The presence of benign and malignant breast lesions was recorded. The number of terminal duct–lobule units (TDLUs) per ten low‐power fields (LPFs) was quantified. Information on hormone therapy and morphometry was retrieved for selected patients.
The cohort included 344 subjects with a mean age of 25·8 (range 16–61) years at the time of surgery; the age at surgery decreased significantly over time. Older individuals presented with a significantly higher number of breast lesions. The number of TDLUs per LPF was lower in heavier breasts, but did not correlate with age. Breast lesions, either benign or malignant, were present in 166 individuals (48·3 per cent). Invasive breast cancer was found in two (0·6 per cent); one tumour was an unexpected finding. The number of breast lesions encountered on histopathological examination increased significantly when more tissue blocks were taken.
The discovery of an unexpected breast cancer in a 31‐year‐old transman emphasizes the importance of thorough routine histopathological examination of mastectomy specimens. The number of tissue blocks taken should be based on age and breast weight.Read more
You may also be interested in
Population‐based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node‐positive invasive lobular carcinoma of the breast.
Authors: E. Morrow, A. Lannigan, J. Doughty, J. Litherland, J. Mansell, S. Stallard et al.
Notes: Less sensitive in ILC
Meta‐analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. BJS 2018; 105: 469-481.
Authors: A. Karakatsanis, M. K. Tasoulis, F. Wärnberg, G. Nilsson, F. MacNeill
Notes: Still unnecessary mastectomies
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non‐surgical management of triple‐negative breast cancer. BJS 2018; 105: 535-543.
Authors: R. F. D. van la Parra, A. B. Tadros, C. M. Checka, G. M. Rauch, A. Lucci, B. D. Smith et al.
Notes: Ductal carcinoma in situ and microcalcification important
Authors: Z. E. Winters, J. R. Benson
Impact of specialist management on survival from radiation‐associated angiosarcoma of the breast. BJS 2018; 105: 401-409.
Authors: L. Feinberg, A. Srinivasan, J. K. Singh, M. Parry, J. Stevenson, L. Jeys et al.
Notes: Improves outcomes
Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative. BJS 2018; 105: e158-e168.
Authors: L. Rydén, N. Loman, C. Larsson, C. Hegardt, J. Vallon‐Christersson, M. Malmberg et al.
Notes: Promising Swedish initiative
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Authors: P. McAnena, A. Lowery, M. J. Kerin
Notes: Promising technology
MiR‐128 regulation of glucose metabolism and cell proliferation in triple‐negative breast cancer. BJS 2018; 105: 75-85.
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Notes: New molecular target?
International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction. BJS 2018; 105: 209-222.
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
Notes: Useful tool
Axillary tumour burden in women with a fine‐needle aspiration/core biopsy‐proven positive node on ultrasonography compared to women with a positive sentinel node. BJS 2017; 104: 1811-1815.
Authors: P. Lloyd, E. Theophilidou, R. G. Newcombe, L. Pugh, A. Goyal
Notes: Axillary ultrasound can detect low‐volume metastases
Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. BJS 2017; 104: 1675-1685.
Authors: A. Karakatsanis, K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson et al.
Notes: Simplifies logistics